ANI Pharmaceuticals Launches Generic Estradiol Gel Following FDA Approval
核心洞察
ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.06%, a generic version of EstroGel.
The launch of Estradiol Gel, 0.06% expands ANI's portfolio of limited-competition products, ensuring greater access for patients in need.
According to August 2024 MAT IQVIA data, U.S. annual sales for Estradiol Gel, 0.06% totaled approximately $16.7 million.
ANI Pharmaceuticals, Inc. has announced the FDA approval and subsequent launch of Estradiol Gel, 0.06%, a generic equivalent to EstroGel. This development aims to provide a more accessible option for patients requiring estradiol treatment.
Nikhil Lalwani, President and Chief Executive Officer of ANI, stated, "With the FDA approval and commercialization of Estradiol Gel, 0.06%, we are pleased to bring another limited-competition product to market and ensure that customers and patients in need have ready access."
The approval was granted following the submission of an Abbreviated New Drug Application (ANDA). According to August 2024 moving annual total (MAT) IQVIA data, the U.S. market for Estradiol Gel, 0.06% is approximately $16.7 million annually.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and marketing both branded and generic prescription drugs. Their portfolio includes treatments for diseases with high unmet medical needs. The company aims to achieve sustainable growth by expanding its Rare Disease business, strengthening its Generics business, innovating in Established Brands, and leveraging its U.S.-based manufacturing capabilities.